Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Hikma Pharmaceuticals ADR HKMPY

Healthcare
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCPK:HKMPY)

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

PR Newswire February 21, 2024

Hikma announces US launch of COMBOGESIC® IV

PR Newswire February 5, 2024

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Business Wire January 8, 2024

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

PR Newswire October 3, 2023

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox(TM) Platform Cancer Treatment in the Middle East and North Africa

PR Newswire August 10, 2023

Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

PR Newswire July 26, 2023

Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP

PR Newswire June 15, 2023

Hikma expands impact in Canada with launches of new sterile injectable medicines

PR Newswire March 9, 2023

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

GlobeNewswire December 26, 2022
View More News ››

Opinion & Analysis (OTCPK:HKMPY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCPK:HKMPY)

Opioids Market Size, Share, Trends and Forecast 2022-2027

According to IMARC Group’s latest report, titled “Opioids Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...
edwardebreen15 - August 23, 2022
View more Bullboard ››

NurExone Biologic Inc.

NurExone Biologic Inc.

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ...
View More »